An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma
Phase of Trial: Phase II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 10 Jun 2017 Biomarkers information updated
- 01 May 2017 Planned primary completion date changed from 1 Jun 2018 to 18 Apr 2018.
- 23 Feb 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2018.